Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palopegteriparatide - Ascendis Pharma

Next Previous
Drug Profile

Palopegteriparatide - Ascendis Pharma

Alternative Names: ACP 014; TransCon parathyroid hormone; TransCon PTH - Ascendis Pharma; TransCon PTH low-dose pen; TransCon™ PTH; YORVIPATH

Latest Information Update: 30 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Developer Ascendis Pharma; Teijin; VISEN Pharmaceuticals
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoparathyroidism

Most Recent Events

  • 24 Jul 2025 Ascendis Pharma plans a phase III trial for Hypoparathyroidism (SC), November 2025 (NCT07081997)
  • 14 Jul 2025 Updated efficacy and adverse events data from week 156 of the phase III PaTHway trial in Hypoparathyroidism released by Ascendis Pharma
  • 12 May 2025 Updated four years result from a phase II PaTH Forward trial in Hypoparathyroidism released by Ascendis Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top